SCHEMBL29947384

SCHEMBL29947384

Brc1ccccc1-c1ccon1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 4/20 0.41
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 5/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
PBRM1 Q86U86 1/20 0.36
MDM2 Q00987 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2122850 1.00 IDO1 (0.44) IDO1LMNAHSD17B10MAPK1ALDH1A1
SCHEMBL4059082 0.84 MDM2 (0.41) ALDH1A1RAB9AMAPTSMN1; SMN2NPC1
SCHEMBL28307279 0.76 RAB9A (0.41) MAPK1ALDH1A1RAB9AMAPTSMN1; SMN2
SCHEMBL30538068 0.75 IDO1 (0.44) IDO1MAPK1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL5542787 0.75 MDM2 (0.36) ALDH1A1RAB9AMAPTSMN1; SMN2NPC1
SCHEMBL29840696 0.75 IDO1 (0.46) IDO1LMNAALDH1A1RAB9AMAPT
SCHEMBL2122583 0.75 NPC1 (0.45) IDO1LMNAHSD17B10ALDH1A1RAB9A
SCHEMBL700662 0.75 ALDH1A1 (0.48) IDO1HSD17B10ALDH1A1RAB9AMAPT
SCHEMBL4714608 0.75 CASP3 (0.44) IDO1LMNAHSD17B10MAPK1ALDH1A1
SCHEMBL1176651 0.75 MDM2 (0.36) ALDH1A1RAB9AMAPTNPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-04-17 US disclosed
CN-118903118-A Use of 3-substituted naphtho [2,3-b ] isoxazole-4, 9-dione derivatives for anti-psoriasis 中南大学 2024-11-08 CN disclosed
EP-4301468-A1 FGFR3 INHIBITOR COMPOUNDS Eli Lilly and Company (US) 2024-01-10 EP disclosed
WO-2022187443-A1 FGFR3 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2022-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS FGFR3, FGFR1, FGFR2 IDO1 1798/4885LMNA 2412/4885HSD17B10 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.